Hangzhou Quandian Medical Technology Co., Ltd., as an innovative company in digital medical care, is committed to helping small and medium-sized medical and health institutions to improve their diagnosis and treatment service capabilities.

The R&D team is composed of interdisciplinary experts in medicine and informatics. The founder and CEO is a clinical doctor of surgery at Peking Union Medical College and a postdoctoral fellow at Johns Hopkins School of Medicine; the co-founder is a senior technical expert from the original Ali; Years of overseas IT work experience.

Zhengxiang Pharmaceutical is a clinical-stage biopharmaceutical company founded in 2018 by a returned technical team with many years of successful drug research and development experience. Headquartered in Nanjing, it has branches in Hangzhou and the San Francisco Bay Area, responsible for preclinical and clinical research. Zhengxiang Medicine is committed to solving clinical needs and serving patients. Currently focusing on the development of new small molecule drugs for cancer, viral infections and autoimmune diseases.

Zhengxiang Pharmaceutical's R&D pipeline includes best-in-class and first-in-class drug molecules, targeting and regulating key biological pathways, preventing virus replication, enhancing immune cell activity and overcoming drug resistance.

Luoxin Pharmaceutical Group Co., Ltd. (stock code: 002793) is a large pharmaceutical enterprise group integrating drug research and development, production, trade and medical and health services. Since 2006, the company has continuously entered the top 100 enterprises in China's pharmaceutical industry. Since 2011, it has been continuously rated as the best industrial enterprise in China's pharmaceutical R&D product line. It is a national industrial quality benchmark enterprise, a national key high-tech enterprise, and a national technology innovation demonstration enterprise.

The company adheres to the strategic policy of "revitalizing the enterprise through science and technology", and has set up a scientific research center in Shanghai Zhangjiang High-tech Park. The scientific research team formed by high-end scientific and technological talents at home and abroad, with the help of various advantageous resources in Zhangjiang High-tech Park, undertakes the research and development of high-tech projects of the group And the training of high-tech talents, and the headquarters have formed a three-in-one scientific research system, which will promote the development of new drugs more strongly. The company has a nationally recognized enterprise technology center, a national and local joint engineering laboratory, a national post-doctoral research station, the post of "Taishan Scholar and a Distinguished Expert in Pharmacy", a Shandong Provincial Enterprise Academician Workstation, Shandong Provincial Freeze-dried Powder Injection Drug Engineering Technology Research Center, Shandong Provincial freeze-dried powder injection drug engineering laboratory, Shandong province freeze-dried powder injection drug key laboratory, Shenyang Pharmaceutical University has established Luoxin Pharmaceutical post-doctoral mobile workstation, teaching training base, practice base, graduate employment base, forming a strong The state-level scientific research and technology center has injected vitality into the rapid development of the enterprise.

With the development concept of "serving the public and creating value", the company is committed to the research and development of innovative drugs and generic drugs. Innovative drug research and development focuses on the research of liver diseases, cancer treatment, and autoimmune diseases, creating clinically urgently needed drugs; The research and development of generic drugs mainly practices the drug marketing license holder system (MAH), has a drug lifecycle quality management system, and gradually provides systematic professional services to the industry. In the process of drug exploration and research and development, the company is gradually realizing an industrialized development model based on generic drugs and driven by innovative drugs.

The company takes technology and innovation as its core strategy, uses independently developed pharmaceutical technology platforms and innovative drug research and development platforms to conduct drug research and development based on technology platforms, and maturely utilizes technologies such as skeleton tablet sustained release technology, pellets sustained and controlled release technology, LipoDose technology, and innovative drug development technology to continuously enrich the company's product line and bring scientific and safe prevention and treatment solutions to society.